Sai Parenteral's (NSE:SAIPARENT) Ending Cash Position: ₹154 Mil (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:SAIPARENT Sai Parenteral's Ltd NSE:SAIPARENT
14 GF Score
Price ₹569.70
! 7 Warning Signs
View Full Analysis

What is Sai Parenteral's Ending Cash Position?

Sai Parenteral's NSE:SAIPARENT +5.28% 14 Ending Cash Position is ₹154 Mil as of Sep. 2025. GuruFocus rates NSE:SAIPARENT with a GF Score™ of 14/100. The stock has 7 warning signs investors should review.

Sai Parenteral's's Ending Cash Position for the quarter that ended in Sep. 2025 was ₹154 Mil.

Sai Parenteral's's quarterly Ending Cash Position stayed the same from Mar. 2024 (₹0 Mil) to Mar. 2025 (₹0 Mil) but then increased from Mar. 2025 (₹0 Mil) to Sep. 2025 (₹154 Mil).

Sai Parenteral's's annual Ending Cash Position increased from Mar. 2023 (₹19 Mil) to Mar. 2024 (₹44 Mil) but then declined from Mar. 2024 (₹44 Mil) to Mar. 2025 (₹21 Mil).

Sai Parenteral's Ending Cash Position Related Terms

Sai Parenteral's Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Sai Parenteral's's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sai Parenteral's Ending Cash Position Chart

Sai Parenteral's Annual Data
Trend Mar23 Mar24 Mar25
Ending Cash Position
19.05 43.84 20.86

Sai Parenteral's Semi-Annual Data
Mar23 Mar24 Mar25 Sep25
Ending Cash Position 0.00 0.00 0.00 154.20
NSE:SAIPARENT
14GF Score
Sai Parenteral's Ltd NSE:SAIPARENT
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sai Parenteral's Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Sai Parenteral's's Ending Cash Position for the fiscal year that ended in Mar. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=43.83+-22.97
=21

Sai Parenteral's's Ending Cash Position for the quarter that ended in Sep. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=20.86+133.34
=154

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of ₹154 Mil mean?
Sai Parenteral's (NSE:SAIPARENT) has a Ending Cash Position of ₹154 Mil as of Sep. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Sai Parenteral's and its competitors.
Is Sai Parenteral's' Ending Cash Position too high?
Sai Parenteral's' current Ending Cash Position is ₹154 Mil. Overall, Sai Parenteral's has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Sai Parenteral's' Ending Cash Position compare to LLY and JNJ?
Sai Parenteral's' Ending Cash Position of ₹154 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Drug Manufacturers company?
A good Ending Cash Position depends on the Drug Manufacturers industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Sai Parenteral's and its competitors. Sai Parenteral's's current Ending Cash Position is ₹154 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sai Parenteral's stock overvalued right now?
Sai Parenteral's (NSE:SAIPARENT) has a current Ending Cash Position of ₹154 Mil. The current Ending Cash Position is ₹154 Mil. Sai Parenteral's' overall GF Score™ is 14/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Sai Parenteral's (NSE:SAIPARENT), the current Ending Cash Position is ₹154 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Sai Parenteral's Business Description

Other Exchanges 544742:India
Address Plot No 39, 5th floor, Lavanya Arcade Jayabheri Enclave, Gachibowli, K.V.Rangareddy, Seri Lingampally, Hyderabad, TG, IND, 500032
Sai Parenteral's Ltd is a diversified pharmaceutical formulations company. Its business is organised in two verticals: (i) Branded Generic Formulations: Through the branded generics portfolio, it serves the domestic market with formulations across multiple therapeutic areas. and (ii) Contract Development and Manufacturing Organisation (CDMO): It provides CDMO services to pharmaceutical companies, supporting activities from product development to commercial manufacturing. Its product portfolio includes cardiovascular care, neuropsychiatry, anti-diabetic therapy, respiratory health, antibiotics, gastroenterology, vitamins, etc. The majority of the company's revenue is derived from the Branded Generic Formulations business.
14GF Score

Get the complete analysis for NSE:SAIPARENT

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹569.70
Price